Literature DB >> 17328823

A day in the life of a nebulizer: surveillance for bacterial growth in nebulizer equipment of children with cystic fibrosis in the hospital setting.

Catherine A O'Malley1, Stacy L VandenBranden, Xiaotian T Zheng, Anne M Polito, Susanna A McColley.   

Abstract

BACKGROUND: Cystic fibrosis (CF) is characterized by chronic lung infection. Minimizing exposure to pathogens is important. Treating a CF pulmonary exacerbation includes nebulizer therapies, but little is known about pathogen exposure from nebulizer equipment in CF.
OBJECTIVE: To assess microbial growth in nebulizer equipment used by hospitalized CF patients. HYPOTHESIS: The small-volume nebulizer would not support the growth of the important CF pathogens: Pseudomonas aeruginosa, Staphylococcus aureus, Haemophilus influenzae, and Burkholderia cepacia.
METHODS: During a 6-month period, we prospectively enrolled 30 patients who were admitted for pulmonary exacerbation of CF and were prescribed an aerosolized bronchodilator 4 times daily. Bronchodilator was administered via disposable small-volume nebulizer, prior to airway clearance. The nebulizer was not cleaned or disinfected between treatments, but instead was replaced after 24 hours. Sputum or throat cultures were obtained prior to admission or on the day of admission, and standard culture techniques were used for CF microbes. After the first bronchodilator treatment, a sample was taken from the residual fluid inside the nebulizer cup. The second, third, and fourth samples were taken from the nebulizer cup after it was filled with a unit dose of the bronchodilator but prior to administering the bronchodilator. At the 24th hour, the nebulizer was filled with 3 mL of sterile water, from which the fifth sample was obtained, then the nebulizer was disposed of.
RESULTS: On respiratory culture, ten patients had Pseudomonas aeruginosa, 5 had both P. aeruginosa and S. aureus, 6 had only S. aureus, and 1 had both S. aureus and H. influenzae. Three had other organisms, 4 had normal flora, and 1 had no culture data. Of the 150 nebulizer sample cultures, only 3 showed bacterial growth. Bacillus species, Corynebacterium, coagulase-negative Staphylococcus, and Candida albicans were isolated at low colony counts.
CONCLUSIONS: We suspect that the organisms identified were caused by skin contamination of the samples rather than contamination of the nebulizer cup. We conclude that there is a low risk of microbial contamination with CF pathogens from the interior of a disposable nebulizer over a 24 hour period.

Entities:  

Mesh:

Year:  2007        PMID: 17328823

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  5 in total

1.  Modulation of immune response by interleukin-10 in systemic Corynebacterium kutscheri infection in mice.

Authors:  Eui-Suk Jeong; Kyoung-Sun Lee; Seung-Ho Heo; Jin-Hee Seo; Yang-Kyu Choi
Journal:  J Microbiol       Date:  2012-04-27       Impact factor: 3.422

Review 2.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 3.  Nebuliser hygiene in cystic fibrosis: evidence-based recommendations.

Authors:  Jane Bell; Lauren Alexander; Jane Carson; Amanda Crossan; John McCaughan; Hazel Mills; Damian O'Neill; John E Moore; B Cherie Millar
Journal:  Breathe (Sheff)       Date:  2020-06

4.  Effect that an educational program for cystic fibrosis patients and caregivers has on the contamination of home nebulizers.

Authors:  Adriana Della Zuana; Doroti de Oliveira Garcia; Regina Célia Turola Passos Juliani; Luiz Vicente Ribeiro Ferreira da Silva Filho
Journal:  J Bras Pneumol       Date:  2014 Mar-Apr       Impact factor: 2.624

Review 5.  Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19.

Authors:  Arzu Ari
Journal:  Respir Med       Date:  2020-04-21       Impact factor: 4.582

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.